Boiron SA (BOI) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Boiron SA €31.00, price €19.80, upside +56.6%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Boiron SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range €19.80 – €38.90 · fair‑value band €21.87 – €39.41 · the €19.80 price screens below the €31.00 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Boiron in your weekly email
Every Wednesday you see whether Boiron is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices, invitro diagnostics, herbal medicine, food supplements, cosmetics, and CBD-based products.
Show more
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices, invitro diagnostics, herbal medicine, food supplements, cosmetics, and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is based in Messimy, France.
Stock analysis
Boiron SA (BOI) currently trades at €19.80, while our model-based Fair Value estimate is €31.00, implying the stock looks roughly 36.1% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €31.96 per share, and 17 of the 24 models we run sit above the €19.80 price.
Bear case: the Dividend Discount group reads lowest at €10.05, and 7 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: €21.87 (bear) to €39.41 (bull), the price of €19.80 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Boiron SA reported revenue of €501M in FY2025 versus €455M in FY2021, a compound +2.4%/yr. Reported net income was €32.6M in FY2025, compounding +3.4%/yr from FY2021.
Key figures
Market cap €477M · P/E ratio 10.5 · P/S ratio 0.69 · EPS (TTM) €1.88 · Dividend yield 6.8% · Net margin 6.5% · Return on equity 8.5% · Return on assets (EBIT) 5.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 57%, BOI screens cheaper than that median.
Fair Value models
Bear €21.87Fair Value €31.00Bull €39.41
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.3877 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.5%
Start year 2020 (pandemic). Over 10 years: −1.9% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+9.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+2.7%
Dividend (yield on the price)6.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3% vs −8%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 7%
Start year 2020 (pandemic)
⚠ Revenue per share shrinking 1.1%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about −4.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks
Beats the industry median on 11/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside+57% · Top 25%
Profitability
Return on equity (TTM)8% · Above median
Return on assets5% · Above median
Net margin (TTM)7% · Below median
Operating margin (TTM)12% · Above median
Growth and dividend
Revenue growth−1% · Below median
Dividend yield (TTM)6.8% · Top 25%
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Boiron SA Fair Value". https://www.fairvalue-calculator.com/stock/BOI
Frequently asked questions
Is Boiron SA (BOI) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €31.00 versus a price of €19.80, about +57% upside (undervalued).
What is the fair value of BOI?
Our model-based fair value for Boiron SA is €31.00 (as of Sep 23, 2026), built from audited fundamentals. The current price: €19.80.
What is the quality score of BOI?
Boiron SA has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Boiron SA (BOI)?
Our model-based price target is the fair value of €31.00 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario €21.87, optimistic scenario €39.41. It is a calculation from audited fundamentals, not an analyst target.
What is the Boiron SA stock forecast for 2026?
Our models put fair value at €31.00, about +57% upside versus a price of €19.80 (undervalued). Cautious scenario €21.87, optimistic scenario €39.41. The calculation is refreshed regularly with new filings.
What is the revenue of Boiron SA (BOI)?
Boiron SA reported trailing-twelve-month revenue of about €501M (latest available figure, as of Sep 23, 2026).
Does Boiron SA pay a dividend?
Boiron SA currently shows a dividend yield of about 6.82% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Boiron SA (BOI)?
For today's price to be fair in a discounted-cash-flow model, Boiron SA would have to grow free cash flow by -2.8 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.5 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of BOI use?
Our models discount Boiron SA at 10.3 %: a base by market capitalisation (small), damped by beta 0.22, country premium for France. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Boiron SA that is -2.8 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Boiron SA (BOI) delivered so far?
Over the past 5 years revenue at Boiron SA grew -0.5 % a year. The price currently implies -2.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Boiron SA (BOI) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Boiron SA (-2.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Boiron SA (BOI)?
The free-cash-flow yield on the price is 8.55 %: that much free cash flow Boiron SA produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Boiron SA (BOI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Boiron SA it is €31.00 per share (as of Sep 23, 2026), against a price of €19.80. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Boiron SA stock overvalued or undervalued in 2026?
As of Sep 23, 2026, BOI trades below its calculated fair value: price €19.80, fair value €31.00, a gap of about +57% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BOI?
No. The price is what the market pays today (€19.80); the fair value is what the company's own numbers justify (€31.00). For Boiron SA the two are €11.20 per share apart. That gap is exactly why we show both numbers side by side.
How much is Boiron SA worth?
The market values Boiron SA at about €477M (market capitalisation, as of Sep 23, 2026). Per share that is €19.80; our models calculate a fair value of €31.00 per share.
What do the bullish and bearish scenarios say about BOI?
Our models span a range for Boiron SA: cautious scenario €21.87, base €31.00, optimistic €39.41 per share (as of Sep 23, 2026, price €19.80). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BOI?
Boiron SA trades at a price-to-earnings ratio of 10.5 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €31.00 is built from several models across several years. Other multiples: PEG 2.4, P/B 1.4, P/S 1.1, EV/EBITDA 6.8.
What is the PEG ratio of BOI?
The PEG ratio of Boiron SA is 2.38 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Boiron SA (BOI)?
Balance-sheet figures for Boiron SA (as of Sep 23, 2026): return on equity 8.5%, debt of 0.01 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is BOI from its 52-week high?
Boiron SA trades at €19.80, about 34% below its 52-week high of €30.21 and at the low of €19.80 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of €31.00 is for.
Which stocks are comparable to Boiron SA?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Boiron SA stock attractive at the current price?
The data as of Sep 23, 2026: price €19.80, calculated fair value €31.00 (+57%), Quality Score 69/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BOI calculated?
We run Boiron SA through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €31.00, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Boiron SA currently trades 57 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Boiron SA (BOI)?
The closing price on Sep 23, 2026 was €19.80. Our model-based fair value is €31.00, about +57% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Boiron SA right now?
The price is below even our cautious bear case (€21.87). The market is more pessimistic than our downside scenario. Solid quality (69/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (€21.87 to €39.41) leaves room in how you read the outcome.
Where does the earnings growth of Boiron SA (BOI) come from?
Earnings per share at Boiron SA grew −10.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share −1.6 %, EBIT margin −13.3 %, tax rate +2.5 %, residual (interest, one-offs) +1.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Boiron SA
How large is the market capitalisation of Boiron SA (BOI)?
The market capitalisation of Boiron SA is €477M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Boiron SA (BOI)?
The price-to-sales ratio of Boiron SA is 0.69 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Boiron SA (BOI)?
Earnings per share at Boiron SA are €1.88 (price ÷ EPS = P/E 10.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Boiron SA (BOI)?
The dividend yield of Boiron SA is 6.8% (payout 71.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Boiron SA (BOI)?
The net margin of Boiron SA is 6.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Boiron SA (BOI)?
The return on equity (ROE) of Boiron SA is 8.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Boiron SA (BOI)?
On an EBIT basis the return on assets of Boiron SA is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Boiron SA (BOI)?
The operating margin of Boiron SA is 11.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Boiron SA (BOI)?
Revenue at Boiron SA is growing −1.4% versus a year earlier (3y avg −2.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Boiron SA (BOI)?
Earnings per share at Boiron SA are growing +166% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Boiron SA (BOI) hold?
Boiron SA holds more cash than debt, €47.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Boiron SA in the live analysis
One click puts Boiron SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
